secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0001104659-25-059400
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar shareholders approve reverse stock split, re-elect directors
----------------------------------------------------------------------

- Elected James V. Caruso and Frederick W. Driscoll as Class II directors; Caruso 5,478,892 for, Driscoll 6,207,218 for.
- Ratified Deloitte & Touche as independent auditor for FY2025 with 16,651,803 votes for, 219,578 against.
- Approved reverse stock split of common stock at ratio 1:10 to 1:30, as determined by Board; 13,464,719 for.
- Approved non-binding advisory vote on named executive officer compensation: 5,050,203 for, 2,230,519 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465925059400/0001104659-25-059400-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465925059400/tm2517987d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-059400

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer